Evidence map›Paper›PMID 27312478›Full record

ArticleJournal of medical case reports2016

Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.

Kosuke Ueda, Shigetaka Suekane, Naoyuki Ogasawara, Katsuaki Chikui, Shunsuke Suyama, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Tsukasa Igawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kosuke UedaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. ueda_kousuke@med.kurume-u.ac.jp.
Shigetaka SuekaneDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Naoyuki OgasawaraDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Katsuaki ChikuiDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Shunsuke SuyamaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Makoto NakiriDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Kiyoaki NishiharaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Mitsunori MatsuoDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Tsukasa IgawaDepartment of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. However, patients in whom the treatment could initially be effective will experience disease progression later. CASE PRESENTATION: A 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction, occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe adverse events.

conclusionsWe present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10 years while receiving sorafenib monotherapy.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Renal CellHumansKidney NeoplasmsLung NeoplasmsMaleNiacinamidePhenylurea CompoundsSorafenibTimeTreatment OutcomeAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenibLong-term responseMonotherapyRenal cell carcinomaSorafenib

Identifiers

PMID27312478
PMCPMC4911686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.